Skip to main content
Top
Published in: World Journal of Surgery 2/2019

Open Access 01-02-2019 | Original Scientific Report

Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance

Authors: Akira Miyauchi, Takumi Kudo, Minoru Kihara, Hitomi Oda, Yasuhiro Ito, Akihiro Miya

Published in: World Journal of Surgery | Issue 2/2019

Login to get access

Abstract

Background

Based on our long-term observation of medullary thyroid carcinoma (MTC) patients, we hypothesized that some MTCs have spontaneous deceleration or regression of tumor growth over a long term and that a minority may acquire growth acceleration. We thus compared the calcitonin doubling time (Ct-DT) in the earlier and later half-periods of MTC patients’ postoperative course.

Methods

We followed 26 MTC patients (14 hereditary and 12 sporadic MTCs) with postoperative hypercalcitoninemia with periodic measurements of serum calcitonin (Ct) for >10 years without major interventions. The median period of Ct measurements was 18.3 years (range 10.6–30.2 years). We divided the individual patients’ study periods into the earlier and later halves and calculated the Ct-DTs for both periods.

Results

In the hereditary group, the Ct-DT in the later half-period (Later-Ct-DT) was significantly longer than that in the earlier half-period (Earlier-Ct-DT) (median 20.0 years vs. 7.1 years, p = 0.013). These values in the sporadic group were 20.0 years versus 11.1 years, respectively (p =0.774). Twelve patients (seven hereditary and five sporadic) had Later-Ct-DTs significantly longer than their Earlier-Ct-DTs (median 27.4 years vs. 4.9 years) and good prognoses. Two patients (one hereditary, one sporadic) had Later-Ct-DTs significantly shorter than their Earlier-Ct-DTs, and both developed structural recurrence and died of the disease.

Conclusion

Many of the hereditary and some of the sporadic MTC patients had elongated Ct-DTs over a long period, suggesting spontaneous deceleration and regression of tumor growth. A minority of the MTC patients showed Ct-DT shortening, suggesting tumor growth acceleration.
Literature
3.
go back to reference Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460CrossRefPubMed Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460CrossRefPubMed
4.
go back to reference Eng C, Smith DP, Mulligan LM et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241CrossRefPubMed Eng C, Smith DP, Mulligan LM et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241CrossRefPubMed
5.
go back to reference Melvin KE, Miller HH, Tashjian AH Jr (1971) Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 285:1115–1120CrossRefPubMed Melvin KE, Miller HH, Tashjian AH Jr (1971) Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N Engl J Med 285:1115–1120CrossRefPubMed
7.
go back to reference van Heerden JA, Grant CS, Gharib H et al (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395–400CrossRefPubMedPubMedCentral van Heerden JA, Grant CS, Gharib H et al (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395–400CrossRefPubMedPubMedCentral
8.
go back to reference Machens A, Niccoli-Sire P, Hoegel J et al (2003) European multiple endocrine neoplasia (EUROMEN) study group: early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525CrossRefPubMed Machens A, Niccoli-Sire P, Hoegel J et al (2003) European multiple endocrine neoplasia (EUROMEN) study group: early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525CrossRefPubMed
9.
go back to reference Miyauchi A, Onishi T, Morimoto S et al (1984) Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461–466CrossRefPubMedPubMedCentral Miyauchi A, Onishi T, Morimoto S et al (1984) Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461–466CrossRefPubMedPubMedCentral
10.
go back to reference Barbet J, Campion L, Kraeber-Bodéré F, GTE Study Group et al (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084CrossRefPubMed Barbet J, Campion L, Kraeber-Bodéré F, GTE Study Group et al (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084CrossRefPubMed
11.
go back to reference Laure Giraudet A, Al Ghulzan A, Aupérin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246CrossRefPubMed Laure Giraudet A, Al Ghulzan A, Aupérin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246CrossRefPubMed
12.
go back to reference Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76:988–1000PubMed Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76:988–1000PubMed
13.
go back to reference Miyauchi A, Matsuzuka F, Kuma K et al (1988) Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels. World J Surg 12:610–615CrossRefPubMed Miyauchi A, Matsuzuka F, Kuma K et al (1988) Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels. World J Surg 12:610–615CrossRefPubMed
14.
go back to reference Wiseman SM, Griffith OL, Deen S et al (2007) Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142:717–727CrossRefPubMed Wiseman SM, Griffith OL, Deen S et al (2007) Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142:717–727CrossRefPubMed
15.
go back to reference Warton DI, Duursma RA, Falster DS et al (2012) smart 3: an R package for estimation and inference about allometric lines. Method Ecol Evol 3:257–259CrossRef Warton DI, Duursma RA, Falster DS et al (2012) smart 3: an R package for estimation and inference about allometric lines. Method Ecol Evol 3:257–259CrossRef
17.
go back to reference Gattiker HH, Wiltshaw E, Galton DA (1980) Spontaneous regression in non-Hodgkin’s lymphoma. Cancer 45:2627–2632CrossRefPubMed Gattiker HH, Wiltshaw E, Galton DA (1980) Spontaneous regression in non-Hodgkin’s lymphoma. Cancer 45:2627–2632CrossRefPubMed
18.
go back to reference Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463CrossRefPubMed Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463CrossRefPubMed
19.
go back to reference Miyauchi A, Kudo T, Kihara M et al (2013) Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J 60:415–421PubMed Miyauchi A, Kudo T, Kihara M et al (2013) Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J 60:415–421PubMed
20.
go back to reference Miyauchi A, Kudo T, Hirokawa M et al (2013) Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J 2:57–64CrossRefPubMedPubMedCentral Miyauchi A, Kudo T, Hirokawa M et al (2013) Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J 2:57–64CrossRefPubMedPubMedCentral
21.
go back to reference Grieco M, Santoro M, Berlingieri MT et al (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–563CrossRefPubMed Grieco M, Santoro M, Berlingieri MT et al (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–563CrossRefPubMed
22.
go back to reference Santoro M, Dathan NA, Berlingieri MT et al (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509–516PubMed Santoro M, Dathan NA, Berlingieri MT et al (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509–516PubMed
23.
go back to reference Kimura ET, Nikiforova MN, Zhu Z et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed Kimura ET, Nikiforova MN, Zhu Z et al (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed
Metadata
Title
Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance
Authors
Akira Miyauchi
Takumi Kudo
Minoru Kihara
Hitomi Oda
Yasuhiro Ito
Akihiro Miya
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 2/2019
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-4789-1

Other articles of this Issue 2/2019

World Journal of Surgery 2/2019 Go to the issue

Original Scientific Report (including Papers Presented at Surgical Conferences)

Emergency Bleeding Control Interventions After Immediate Total-Body CT Scans in Trauma Patients